ATC12 

ATC12 is a Aurora-A kinase inhibitor. ATC12 binds to Aurora-A and competes with TPX2 for binding to disrupt the Aurora-A/TPX2 interaction. ATC12 inhibits cancer cell proliferation, induces apoptosis and cellular senescence. ATC12 can be used in the research of breast cancer^[1].

ATC12 (1.56-100 μM; 10 min) disrupts the interaction between purified Aurora-A^KDCM and the TPX2_1-43 peptide in vitro, with an IC₅₀ of 25.6 μM^[1].
ATC12 (10 μM; 24 h) reduces the formation of the Aurora-A/TPX2 complex on the mitotic spindle and the level of pT288 Aurora-A at spindle poles in U2OS osteosarcoma cells^[1].
ATC12 (10 μM; 24 h) disrupts the formation of Aurora-A/TPX2 complexes in mitotic and interphase nuclei of MCF7 and MDA-MB-231 breast cancer cells, and reduces the nuclear level of Aurora-A^[1].
ATC12 (30-50 μM; 0-48 h) inhibits the proliferation of MCF7 breast cancer cells, prolongs the mitotic process, reduces the cell growth rate, and induces apoptotic cell death^[1].
ATC12 (30-50 μM; 0-72 h) inhibits the proliferation of MDA-MB-231 breast cancer cells, prolongs mitotic duration, reduces cell growth rate and induces cellular senescence without triggering cell death^[1].
ATC12 (10-100 μM; 5 days) reduces the viability of patient-derived organoids BCO-21, BCO-46 and BCO-61 from triple-negative breast cancer (TNBC) in a dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

427.53

C₂₈H₂₉NO₃

384860-40-6

CC(C)(C1=CC(C2=CC(C(O)=O)=C3C4=CC=CC=C4C=CC3=N2)=CC(C(C)(C)C)=C1O)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Boi D, et al. The ATC12 small molecule inhibits the Aurora-A/TPX2 interaction and impairs the proliferation of breast cancer cells. Cell Death Dis. 2026;17(1):356. Published 2026 Mar 24.